Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Return on Capital Employed (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Return on Capital Employed for 14 consecutive years, with 0.17% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed fell 2.0% year-over-year to 0.17%, compared with a TTM value of 0.17% through Dec 2025, down 2.0%, and an annual FY2025 reading of 0.18%, down 1.0% over the prior year.
  • Return on Capital Employed was 0.17% for Q4 2025 at Neurocrine Biosciences, up from 0.16% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.19% in Q3 2024 and bottomed at 0.01% in Q1 2023.
  • Average Return on Capital Employed over 4 years is 0.12%, with a median of 0.13% recorded in 2025.
  • The sharpest move saw Return on Capital Employed decreased -23bps in 2021, then grew 14bps in 2024.
  • Year by year, Return on Capital Employed stood at 0.05% in 2021, then soared by 95bps to 0.1% in 2023, then skyrocketed by 75bps to 0.18% in 2024, then decreased by -9bps to 0.17% in 2025.
  • Business Quant data shows Return on Capital Employed for NBIX at 0.17% in Q4 2025, 0.16% in Q3 2025, and 0.15% in Q2 2025.